Intuitive Announces Increase in Share Repurchase Program

Wed Mar 20, 2013 8:22pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130321:nGNXUXKGTa

SUNNYVALE, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the
industry leader in surgical robotics, today announced that its board of directors has authorized
the Company to repurchase an additional $1 billion of the Company's outstanding common stock. The
$1 billion repurchase authorization will be available after the Company's internal trading window
opens on April 23, 2013. With this authorization, the total amount available for share repurchases
by the Company is approximately $1.21 billion, which includes approximately $208 million remaining
from previous authorizations.

The timing and total amount of share repurchases will depend upon market conditions and may be
made from time to time in open market purchases, privately negotiated transactions, accelerated
stock repurchase programs, issuer self-tender offers or otherwise, as determined by the Company's
management. The repurchases will be made in compliance with, and at such times as permitted by,
federal securities law and may be suspended or discontinued at any time. The Company expects to
fund the repurchase program through cash and investments. As of December 31, 2012, the Company had
approximately $2.9 billion of cash, cash equivalents and investments.

About Intuitive Surgical's Products

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, California, is the global
technology leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops,
manufactures and markets robotic technologies designed to improve clinical outcomes and help
patients return more quickly to active and productive lives. Intuitive Surgical's mission is to
extend the benefits of minimally invasive surgery to the broadest possible base of patients.
Intuitive Surgical - Taking surgery beyond the limits of the human hand.

About the da Vinci® Surgical System

The da Vinci® Surgical System is a breakthrough surgical platform designed to enable complex
surgery using a minimally invasive approach. The da Vinci® Surgical System consists of an
ergonomic surgeon console or consoles, a patient-side cart with three or four interactive robotic
arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by
state-of-the-art robotic and computer technology, the da Vinci® Surgical System is designed to
scale, filter and seamlessly translate the surgeon's hand movements into more precise movements of
the EndoWrist® instruments. The net result is an intuitive interface with breakthrough surgical
capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater
precision and ergonomic comfort, the da Vinci® Surgical System makes it possible for more surgeons
to perform minimally invasive procedures involving complex dissection or reconstruction. This
ultimately has the potential to raise the standard of care for complex surgeries, translating into
numerous potential patient benefits, including less pain, a shorter recovery and quicker return to
normal daily activities. For more information about clinical evidence related to da Vinci®
Surgery, please visit www.intuitivesurgical.com/company/clinical-evidence/
http://www.globenewswire.com/newsroom/ctr?d=10025131&l=10&a=www.intuitivesurgical.com%2Fcompany%2Fclinical-evidence%2F&u=http%3A%2F%2Fwww.intuitivesurgical.com%2Fcompany%2Fclinical-evidence%2F


Intuitive®, Intuitive Surgical®, da Vinci®, da Vinci S®, da Vinci® S HD Surgical System, da Vinci®
Si, da Vinci® Si-eTM Surgical System, EndoWrist®, EndoWrist® One, Single-SiteTM, DVSTAT®, Firefly
Fluorescence Imaging and InSite® are trademarks or registered trademarks of Intuitive Surgical,
Inc.

This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding the amount of stock that
the Company may repurchase in the open market, the amount of cash that may be available for stock
repurchases, and the timing and form of stock repurchase transactions. These forward-looking
statements are necessarily estimates reflecting the best judgment of our management and involve a
number of risks and uncertainties that could cause actual results to differ materially from those
suggested by the forward-looking statements. These forward-looking statements should, therefore,
be considered in light of various important factors, including the following: the impact of global
and regional economic and credit market conditions on health care spending; health care reform
legislation in the United States and its implications on hospital spending, reimbursement and fees
which will be levied on certain medical device revenues; timing and success of product development
and market acceptance of developed products; procedure counts; regulatory approvals, clearances
and restrictions; guidelines and recommendations in the health care and patient communities;
intellectual property positions and litigation; competition in the medical device industry and in
the specific markets of surgery in which we operate; unanticipated manufacturing disruptions or
the inability to meet demand for products; the results of legal proceedings to which we are or may
become a party; our ability to expand into foreign markets; and other risk factors under the
heading "Risk Factors"' in our report on Form 10-K for the year ended December 31, 2012, as
updated from time to time by our quarterly reports on Form 10-Q and our other filings with the
Securities and Exchange Commission. Statements using words such as "estimates," "projects,"
"believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should,"
"would," "targeted" and similar words and expressions are intended to identify forward-looking
statements. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. We undertake no obligation to publicly
update or release any revisions to these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect the occurrence of unanticipated
events.

CONTACT:  Investor Relations
          (408) 523-2161

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.